...
首页> 外文期刊>Molecular Immunology >Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
【24h】

Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.

机译:Syk抑制剂在巨噬细胞中的抗炎作用涉及非特异性抑制toll样受体介导的JNK信号通路。

获取原文
获取原文并翻译 | 示例
           

摘要

Toll-like receptors (TLRs) are a major family of pattern recognition receptors (PRRs) and play a crucial role in innate immune system. Even though non-receptor spleen tyrosine kinase (Syk) is a key signaling molecule of immunoreceptor tyrosine-based activation motifs-containing immunoreceptors, its role in TLRs signaling is not clearly understood. Herein, we investigated the role of Syk in TLR-mediated signaling and gene regulation. In bone marrow-derived macrophages (BMDMs) and RAW 264.7 macrophages, treatment of poly(I:C), LPS and CpG, which are specific ligands of TLR3, TLR4 and TLR9, respectively, can increase the mRNA levels of several pro-inflammatory cytokines and mediators, including IFNbeta, TNFalpha, MIP2, IL-6, IL-12beta, iNOS and COX-2. The gene upregulation caused by TLR was inhibited by Syk inhibitor (SykI) and JNK inhibitor (SP600125). Accordingly we found the abilities of TLR3, TLR4 and TLR9 ligands to induce Syk and JNK activation, as evidenced by increased Syk autophosphorylation on Y519/Y520, JNK phosphorylation and both kinase activities. We also found that TLRs-mediated JNK activation, but not IKK, p38 and ERK activation as well as IkappaB degradation in BMDM and RAW 264.7 cells, was blocked by SykI. Nevertheless TLR-mediated JNK activation as well as the increased protein expression of iNOS and COX-2 remained unchanged when Syk protein was knockdown by siRNA approach. With in vitro kinase assay we found two commercial Syk inhibitors (SykI, and BAY61-3606) have direct inhibition on JNK activity. These findings demonstrate that the non-selective action of SykI on JNK should be taken into consideration upon using them to explore the biological actions of Syk.
机译:Toll样受体(TLR)是模式识别受体(PRR)的主要家族,在先天免疫系统中起关键作用。即使非受体脾酪氨酸激酶(Syk)是包含基于免疫受体酪氨酸的活化基序的免疫受体的关键信号分子,但其在TLRs信号传导中的作用仍不清楚。在本文中,我们调查了Syk在TLR介导的信号传导和基因调控中的作用。在骨髓来源的巨噬细胞(BMDM)和RAW 264.7巨噬细胞中,分别治疗TLR3,TLR4和TLR9的特异性配体poly(I:C),LPS和CpG可以增加几种促炎性细胞的mRNA水平。细胞因子和介体,包括IFNbeta,TNFalpha,MIP2,IL-6,IL-12beta,iNOS和COX-2。 Syk抑制剂(SykI)和JNK抑制剂(SP600125)抑制了由TLR引起的基因上调。因此,我们发现了TLR3,TLR4和TLR9配体诱导Syk和JNK活化的能力,这在Y519 / Y520上Syk自磷酸化增加,JNK磷酸化和两种激酶活性都得到了证明。我们还发现SykI阻止了TLDMs介导的JNK激活,但未抑制IKDM,p38和ERK激活以及BMDM和RAW 264.7细胞中的IkappaB降解。然而,当通过siRNA方法敲除Syk蛋白时,TLR介导的JNK活化以及iNOS和COX-2蛋白表达的增加保持不变。通过体外激酶测定,我们发现两种商业Syk抑制剂(SykI和BAY61-3606)对JNK活性具有直接抑制作用。这些发现表明,在使用SykI探索Syk的生物学作用时,应考虑SykI对JNK的非选择性作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号